Dapagliflozin: A molecule for type-2 diabetes mellitus
نویسندگان
چکیده
Dapagliflozin which is also known as Farxiga in the US and Forxiga EU a drug was developed by Bristol-Myers Squibb partnership with Astra Zeneca. It available Oxra it marking Sun Pharmaceutical Industries Ltd. contains active substance second member of selective sodium glucose co-transporter-2 (SGLT-2) inhibitor first group among oral anti-diabetic agents are independent insulin secretion. The shows action reducing blood preventing reabsorption at renal proximal tubule avoids resistance. new molecule that helps maintaining glycemic control either mono therapy or combinational add on therapy. This review article summarizes details Dapagliflozin.
منابع مشابه
Dapagliflozin (Farxiga) for Type 2 Diabetes Mellitus.
Because dapagliflozin has been shown to induce glycosuria, patients should be warned about the most common clinical sequelae of osmotic diuresis, hypotension, and hypoglycemia. Systolic blood pressure typically decreases by 2.3 to 5.6 mm Hg. However, hypotension is relatively uncommon (number needed to harm [NNH] = 337) and mainly affects older adults, patients on loop diuretics, and those with...
متن کاملDapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
Sodium-glucose co-transporter 2 inhibitors (SGLT2is) such as dapagliflozin, canagliflozin, and empagliflozin, are a promising new therapy in the treatment of type 2 diabetes mellitus (T2DM). SGLT2is can effectively reduce hyperglycemia thus improving glycemic control and they offer some beneficial effects on the cardiovascular (CV) system which can benefit patients with heart failure in additio...
متن کاملMAP3K1 May be a Promising Susceptibility Gene for Type 2 Diabetes Mellitus in an Iranian Population
Considering that MAPK (mitogen- activated protein kinase) signaling pathway has an important role in the progression of inflammatory cytokine secretion in type 2 diabetes mellitus (T2DM), we have recently investigated the reported genetic polymorphism from genome wide association study in MAP3K1 (mitogen-activated protein kinase kinase kinase 1) in diabetes as an important member of MAPK signal...
متن کاملInfluence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with HbA1c levels of 7.5-10.5% were randomly selected to receive dapagliflozin or placebo treatment ...
متن کاملPrevalence of Onychomycosis in Type 2 Diabetes Mellitus
Abstract Background and Objective: Onychomycosis is a fungal nail infection causing ulcers, diabetic foot and enhance nail infection. This study was designed to evaluate the prevalence of onychomycosis in type II diabetes. Material and methods: This descriptive-analytic study was conducted on 300 diabetic patients selected randomly among those referred to Panje Azar endocrinology clinic. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International journal of pharmaceutical chemistry and analysis
سال: 2023
ISSN: ['2394-2789', '2394-2797']
DOI: https://doi.org/10.18231/j.ijpca.2022.029